Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
FORA vs MMSI vs ITGR vs INFU vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
FORA vs MMSI vs ITGR vs INFU vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $68M | $4.01B | $3.13B | $190M | $1.62B |
| Revenue (TTM) | $30M | $1.54B | $1.85B | $142M | $674M |
| Net Income (TTM) | $-5M | $139M | $142M | $8M | $-173M |
| Gross Margin | 46.8% | 48.7% | 23.3% | 56.7% | 75.2% |
| Operating Margin | -13.4% | 12.2% | 10.4% | 9.1% | -27.2% |
| Forward P/E | — | 16.5x | 15.0x | 22.2x | — |
| Total Debt | $12K | $898M | $1.40B | $3M | $290M |
| Cash & Equiv. | $13M | $449M | $17M | $3M | $103M |
FORA vs MMSI vs ITGR vs INFU vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Forian Inc. (FORA) | 100 | 21.5 | -78.5% |
| Merit Medical Syste… (MMSI) | 100 | 113.9 | +13.9% |
| Integer Holdings Co… (ITGR) | 100 | 96.1 | -3.9% |
| InfuSystem Holdings… (INFU) | 100 | 49.8 | -50.2% |
| NovoCure Limited (NVCR) | 100 | 11.5 | -88.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FORA vs MMSI vs ITGR vs INFU vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FORA has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.21
- Rev growth 50.1%, EPS growth 23.0%, 3Y rev CAGR 22.6%
- Lower volatility, beta 0.21, Low D/E 0.0%, current ratio 2.97x
- 50.1% revenue growth vs INFU's 6.4%
MMSI ranks third and is worth considering specifically for long-term compounding and defensive.
- 249.4% 10Y total return vs INFU's 240.1%
- Beta 0.58, current ratio 4.34x
- 9.0% margin vs NVCR's -25.7%
ITGR is the clearest fit if your priority is value.
- Better valuation composite
INFU is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +52.2% vs MMSI's -27.7%
- 7.9% ROA vs NVCR's -16.5%, ROIC 12.5% vs -16.4%
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 50.1% revenue growth vs INFU's 6.4% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.0% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.21 vs NVCR's 2.00, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +52.2% vs MMSI's -27.7% | |
| Efficiency (ROA) | 7.9% ROA vs NVCR's -16.5%, ROIC 12.5% vs -16.4% |
FORA vs MMSI vs ITGR vs INFU vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FORA vs MMSI vs ITGR vs INFU vs NVCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INFU leads in 2 of 6 categories
MMSI leads 1 • ITGR leads 1 • FORA leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
MMSI leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ITGR is the larger business by revenue, generating $1.8B annually — 61.6x FORA's $30M. MMSI is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $30M | $1.5B | $1.8B | $142M | $674M |
| EBITDAEarnings before interest/tax | -$4M | $290M | $328M | $26M | -$165M |
| Net IncomeAfter-tax profit | -$5M | $139M | $142M | $8M | -$173M |
| Free Cash FlowCash after capex | $2M | $274M | $168M | $20M | -$48M |
| Gross MarginGross profit ÷ Revenue | +46.8% | +48.7% | +23.3% | +56.7% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -13.4% | +12.2% | +10.4% | +9.1% | -27.2% |
| Net MarginNet income ÷ Revenue | -17.0% | +9.0% | +7.7% | +5.6% | -25.7% |
| FCF MarginFCF ÷ Revenue | +7.8% | +17.8% | +9.1% | +14.3% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.9% | +7.8% | +0.8% | -3.0% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.0% | +38.8% | +172.7% | +5.9% | -100.0% |
Valuation Metrics
INFU leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 30.4x trailing earnings, INFU trades at a 4% valuation discount to MMSI's 31.6x P/E. On an enterprise value basis, INFU's 7.5x EV/EBITDA is more attractive than MMSI's 14.0x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $68M | $4.0B | $3.1B | $190M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $55M | $4.5B | $4.5B | $190M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -23.48x | 31.56x | 31.47x | 30.39x | -11.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.51x | 14.95x | 22.16x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 7.15x | — | — |
| EV / EBITDAEnterprise value multiple | — | 13.98x | 13.46x | 7.55x | — |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 2.65x | 1.70x | 1.33x | 2.48x |
| Price / BookPrice ÷ Book value/share | 2.27x | 2.57x | 1.85x | 3.47x | 4.68x |
| Price / FCFMarket cap ÷ FCF | 23.49x | 18.59x | 29.77x | 7.97x | — |
Profitability & Efficiency
INFU leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INFU delivers a 14.0% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-51 for NVCR. FORA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs NVCR's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.2% | +8.9% | +8.2% | +14.0% | -50.8% |
| ROA (TTM)Return on assets | -11.8% | +5.2% | +4.2% | +7.9% | -16.5% |
| ROICReturn on invested capital | -7.5% | +7.2% | +5.4% | +12.5% | -16.4% |
| ROCEReturn on capital employed | -8.2% | +7.9% | +6.9% | +14.3% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.00x | 0.57x | 0.80x | 0.06x | 0.85x |
| Net DebtTotal debt minus cash | -$13M | $450M | $1.4B | $241,000 | $187M |
| Cash & Equiv.Liquid assets | $13M | $449M | $17M | $3M | $103M |
| Total DebtShort + long-term debt | $12,137 | $898M | $1.4B | $3M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -48.78x | 10.74x | 5.07x | 15.54x | -96.80x |
Total Returns (Dividends Reinvested)
ITGR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MMSI five years ago would be worth $11,159 today (with dividends reinvested), compared to $655 for NVCR. Over the past 12 months, INFU leads with a +52.2% total return vs MMSI's -27.7%. The 3-year compound annual growth rate (CAGR) favors ITGR at 2.1% vs NVCR's -31.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.4% | -22.2% | +18.5% | +12.3% | +8.8% |
| 1-Year ReturnPast 12 months | +2.4% | -27.7% | -23.5% | +52.2% | -15.0% |
| 3-Year ReturnCumulative with dividends | -7.3% | -18.9% | +6.5% | -7.6% | -67.6% |
| 5-Year ReturnCumulative with dividends | -82.7% | +11.6% | +0.9% | -50.2% | -93.5% |
| 10-Year ReturnCumulative with dividends | -90.5% | +249.4% | +183.0% | +240.1% | +22.4% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -6.8% | +2.1% | -2.6% | -31.3% |
Risk & Volatility
Evenly matched — FORA and INFU each lead in 1 of 2 comparable metrics.
Risk & Volatility
FORA is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than NVCR's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INFU currently trades 85.3% from its 52-week high vs MMSI's 69.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.21x | 0.58x | 0.69x | 1.22x | 2.00x |
| 52-Week HighHighest price in past year | $2.71 | $96.74 | $123.78 | $11.04 | $18.92 |
| 52-Week LowLowest price in past year | $1.64 | $59.74 | $62.00 | $5.38 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +80.1% | +69.5% | +73.5% | +85.3% | +75.5% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 50.7 | 47.8 | 41.5 | 57.6 |
| Avg Volume (50D)Average daily shares traded | 40K | 706K | 463K | 172K | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MMSI as "Buy", ITGR as "Buy", INFU as "Buy", NVCR as "Buy". Consensus price targets imply 131.1% upside for NVCR (target: $33) vs 18.7% for ITGR (target: $108).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $94.20 | $108.00 | $15.00 | $33.00 |
| # AnalystsCovering analysts | — | 14 | 15 | 3 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% | +1.6% | +5.8% | 0.0% |
INFU leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). MMSI leads in 1 (Income & Cash Flow). 1 tied.
FORA vs MMSI vs ITGR vs INFU vs NVCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FORA or MMSI or ITGR or INFU or NVCR a better buy right now?
For growth investors, Forian Inc.
(FORA) is the stronger pick with 50. 1% revenue growth year-over-year, versus 6. 4% for InfuSystem Holdings, Inc. (INFU). InfuSystem Holdings, Inc. (INFU) offers the better valuation at 30. 4x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate Merit Medical Systems, Inc. (MMSI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FORA or MMSI or ITGR or INFU or NVCR?
On trailing P/E, InfuSystem Holdings, Inc.
(INFU) is the cheapest at 30. 4x versus Merit Medical Systems, Inc. at 31. 6x. On forward P/E, Integer Holdings Corporation is actually cheaper at 15. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — FORA or MMSI or ITGR or INFU or NVCR?
Over the past 5 years, Merit Medical Systems, Inc.
(MMSI) delivered a total return of +11. 6%, compared to -93. 5% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MMSI returned +249. 4% versus FORA's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FORA or MMSI or ITGR or INFU or NVCR?
By beta (market sensitivity over 5 years), Forian Inc.
(FORA) is the lower-risk stock at 0. 21β versus NovoCure Limited's 2. 00β — meaning NVCR is approximately 852% more volatile than FORA relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — FORA or MMSI or ITGR or INFU or NVCR?
By revenue growth (latest reported year), Forian Inc.
(FORA) is pulling ahead at 50. 1% versus 6. 4% for InfuSystem Holdings, Inc. (INFU). On earnings-per-share growth, the picture is similar: InfuSystem Holdings, Inc. grew EPS 181. 8% year-over-year, compared to -15. 0% for Integer Holdings Corporation. Over a 3-year CAGR, FORA leads at 22. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FORA or MMSI or ITGR or INFU or NVCR?
Merit Medical Systems, Inc.
(MMSI) is the more profitable company, earning 8. 5% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MMSI leads at 12. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FORA or MMSI or ITGR or INFU or NVCR more undervalued right now?
On forward earnings alone, Integer Holdings Corporation (ITGR) trades at 15.
0x forward P/E versus 22. 2x for InfuSystem Holdings, Inc. — 7. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 131. 1% to $33. 00.
08Which pays a better dividend — FORA or MMSI or ITGR or INFU or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is FORA or MMSI or ITGR or INFU or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Forian Inc.
(FORA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 21)). NovoCure Limited (NVCR) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FORA: -90. 5%, NVCR: +22. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FORA and MMSI and ITGR and INFU and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FORA is a small-cap high-growth stock; MMSI is a small-cap quality compounder stock; ITGR is a small-cap quality compounder stock; INFU is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.